Clinical Trial Update: Single Dose Administration of Alpha-1 Anti-Trypsin for the Amelioration of Organ Injury in Patients Undergoing Cardiac Surgery [Phase 1, Phase 2]

View source ↗

Summary

This document reports a Phase 1/2 clinical trial evaluating a single-dose alpha-1 antitrypsin to reduce organ injury in patients undergoing cardiac surgery who …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Inflammatory Response Syndrome

Drugs mentioned

• Alpha-1 Antitrypsin (alpha-1 antitrypsin)

Snippet

Sponsor: Soroka University Medical Center | Conditions: Post Cardiac Surgery Systemic Inflammatory Response | Phase 1, Phase 2 | Status: UNKNOWN